Drugmakers send counter offers for U.S. Medicare price negotiations, Biden says
Reuters
Published Mar 04, 2024 11:04AM ET
Updated Mar 04, 2024 12:45PM ET
(Reuters) -The manufacturers of 10 high-cost drugs selected for the U.S. Medicare program's first-ever pricing negotiations have submitted counter offers to the U.S. government's initial proposal, U.S. President Joe Biden said on Monday.
The negotiation program, passed as part of 2022's Inflation Reduction Act, allows Medicare to negotiate prices for the high-cost drugs. Medicare covers Americans aged 65 and above.
The agency in August picked the first drugs for such negotiations, then the Biden administration sent its initial offers to manufacturers of the medicines, which include Bristol Myers (NYSE:BMY) Squibb and Pfizer (NYSE:PFE)'s blood thinner Eliquis, in February.
A federal judge in Delaware on Friday upheld the law that requires drugmakers to negotiate prices, rejecting a challenge by AstraZeneca (NASDAQ:AZN)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.